Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Ejemplares similares

• Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
  por: Clare Buckeridge, et al.
  Publicado: (2024)
• Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
  por: Mona Abdel‐Bary, et al.
  Publicado: (2025)
• Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
  por: Jason Zupec, et al.
  Publicado: (2025)
• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  por: Carel W. le Roux, et al.
  Publicado: (2024)
• Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon‐like peptide‐1 agonists
  por: Naadir Jamal, et al.
  Publicado: (2024)